Trial Profile
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2020
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PROGRESS-HF
- Sponsors Stealth BioTherapeutics
- 17 Jul 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2019 This trial has been completed in UK-MHRA, as per European Clinical Trials Database record
- 05 Mar 2018 This trial has been completed in Italy, as per European Clinical Trials Database record.